Payment overview · 2025
General Payments
$1,773.42
61 reported records · 28 companies
Healthcare provider profile · identity verified
Piyush Bhatnagar, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GRAND RAPIDS, MI · NPI 1811961907
Verified facts
What the public records show
CMS Open Payments records show Piyush Bhatnagar, M.D. received $1,773.42 in general payments during 2025 across 61 reported records.
PFIZER INC. accounted for 11.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 249 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 298 claims for Xarelto by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Entresto by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rexulti by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1670 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $208.93 | 11.8% | 9 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $179.62 | 10.1% | 4 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $176.20 | 9.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $175.78 | 9.9% | 5 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $149.95 | 8.5% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $114.10 | 6.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $78.62 | 4.4% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $76.58 | 4.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $73.85 | 4.2% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $52.39 | 3.0% | 3 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $49.53 | 2.8% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $47.59 | 2.7% | 2 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$38.56 | 2.2% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $38.19 | 2.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.48 | 1.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $31.66 | 1.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.83 | 1.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $26.00 | 1.5% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $24.49 | 1.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $23.85 | 1.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.10 | 1.2% | 1 | 2025 |
| Ultragenyx Pharmaceutical Inc. | Unresolved — no canonical attribution shown | $20.58 | 1.2% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $18.73 | 1.1% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $17.49 | 1.0% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.32 | 1.0% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $17.12 | 1.0% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $15.05 | 0.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.83 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,759.66 | 60 |
| Education | $13.76 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | $256.50 | 8 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $176.20 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $155.68 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $149.95 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $114.10 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $78.62 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $76.58 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $73.85 | 4 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $49.53 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $47.59 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $46.12 | 3 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $38.56 | 2 | 2025 |
Source payment records
|
|||||
| EOHILIA Normalized: eohilia |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $38.19 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $34.48 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $33.54 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $31.66 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $31.47 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.83 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.83 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $26.00 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.06 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| Dojolvi Normalized: dojolvi |
Drug | Ultragenyx Pharmaceutical Inc. | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.10 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.10 | 2 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $15.05 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $15.05 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 17 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1670 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 126 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
249 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
126 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
102 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
298 | 29 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
146 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1670 | 137 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2761 | 294 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1937 | 188 |
| Eliquis | Apixaban | 1670 | 137 |
| Amlodipine Besylate | Amlodipine Besylate | 1314 | 174 |
| Furosemide | Furosemide | 1251 | 152 |
| Lisinopril | Lisinopril | 1153 | 118 |
| Gabapentin | Gabapentin | 905 | 109 |
| Sertraline Hcl | Sertraline Hcl | 902 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 886 | 112 |
| Tamsulosin Hcl | Tamsulosin Hcl | 842 | 101 |
| Buspirone Hcl | Buspirone Hcl | 819 | 70 |
| Trazodone Hcl | Trazodone Hcl | 811 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 721 | 101 |
| Potassium Chloride | Potassium Chloride | 720 | 94 |
| Duloxetine Hcl | Duloxetine Hcl | 719 | 72 |
| Escitalopram Oxalate | Escitalopram Oxalate | 661 | 70 |
| Losartan Potassium | Losartan Potassium | 654 | 98 |
| Metformin Hcl | Metformin Hcl | 588 | 88 |
| Carvedilol | Carvedilol | 494 | 71 |
| Metoprolol Tartrate | Metoprolol Tartrate | 490 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 435 | 51 |
| Torsemide | Torsemide | 420 | 58 |
| Mirtazapine | Mirtazapine | 406 | 51 |
| Donepezil Hcl | Donepezil Hcl | 405 | 40 |
| Omeprazole | Omeprazole | 401 | 100 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 395 | 71 |
| Baclofen | Baclofen | 377 | 42 |
| Risperidone | Risperidone | 369 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 365 | 38 |
| Fluoxetine Hcl | Fluoxetine Hcl | 356 | 40 |
| Ondansetron Hcl | Ondansetron Hcl | 351 | 75 |
| Levetiracetam | Levetiracetam | 346 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 339 | 57 |
| Methocarbamol | Methocarbamol | 330 | 80 |
| Finasteride | Finasteride | 325 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 311 | 53 |
| Xarelto | Rivaroxaban | 298 | 29 |
| Bupropion Xl | Bupropion Hcl | 297 | 33 |
| Midodrine Hcl | Midodrine Hcl | 277 | 28 |
| Latanoprost | Latanoprost | 275 | 57 |
| Olanzapine | Olanzapine | 273 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 268 | 43 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 255 | 29 |
| Myrbetriq | Mirabegron | 249 | 24 |
| Divalproex Sodium | Divalproex Sodium | 244 | 33 |
| Simvastatin | Simvastatin | 238 | 30 |
| Aripiprazole | Aripiprazole | 227 | 15 |
| Jardiance | Empagliflozin | 226 | 29 |
| Prednisone | Prednisone | 224 | 63 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 224 | 21 |
| Spironolactone | Spironolactone | 222 | 32 |
| Metformin Hcl Er | Metformin Hcl | 219 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 214 | 23 |
| Warfarin Sodium | Warfarin Sodium | 212 | 11 |
| Allopurinol | Allopurinol | 202 | 34 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 200 | 26 |
| Meloxicam | Meloxicam | 194 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 186 | 34 |
| Memantine Hcl | Memantine Hcl | 180 | 25 |
| Famotidine | Famotidine | 175 | 46 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 174 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 173 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 165 | 14 |
| Alendronate Sodium | Alendronate Sodium | 159 | 22 |
| Entresto | Sacubitril/Valsartan | 146 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 144 | 21 |
| Topiramate | Topiramate | 143 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 136 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 133 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 132 | 46 |
| Montelukast Sodium | Montelukast Sodium | 130 | 28 |
| Cephalexin | Cephalexin | 128 | 51 |
| Farxiga | Dapagliflozin Propanediol | 126 | 15 |
| Verapamil Er | Verapamil Hcl | 125 | suppressed |
| Januvia | Sitagliptin Phosphate | 118 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 116 | 67 |
| Humalog Kwikpen U-100 | Insulin Lispro | 116 | 36 |
| Glimepiride | Glimepiride | 115 | 14 |
| Nifedipine Er | Nifedipine | 115 | suppressed |
| Celecoxib | Celecoxib | 112 | 13 |
| Trulicity | Dulaglutide | 112 | 23 |
| Propranolol Hcl | Propranolol Hcl | 111 | suppressed |
| Digoxin | Digoxin | 108 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 107 | 13 |
| Lokelma | Sodium Zirconium Cyclosilicate | 102 | 16 |
| Metolazone | Metolazone | 101 | 20 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 100 | 24 |
| Atenolol | Atenolol | 98 | 16 |
| Lamotrigine | Lamotrigine | 95 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 92 | 35 |
| Paroxetine Hcl | Paroxetine Hcl | 92 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 89 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 89 | 40 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 88 | 51 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 86 | 54 |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 82 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 82 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 81 | 11 |
| Tramadol Hcl | Tramadol Hcl | 81 | 26 |
| Valsartan | Valsartan | 78 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 77 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 74 | 11 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 74 | 36 |
| Ezetimibe | Ezetimibe | 74 | 15 |
| Glipizide | Glipizide | 72 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 71 | 27 |
| Oxybutynin Chloride | Oxybutynin Chloride | 69 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 69 | suppressed |
| Ondansetron Odt | Ondansetron | 68 | 27 |
| Clonidine Hcl | Clonidine Hcl | 67 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 67 | 11 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 65 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 64 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 64 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 61 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | suppressed |
| Trimethoprim | Trimethoprim | 61 | suppressed |
| Ketoconazole | Ketoconazole | 59 | 14 |
| Diltiazem Hcl | Diltiazem Hcl | 58 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 57 | 38 |
| Trintellix | Vortioxetine Hydrobromide | 57 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | suppressed |
| Nystatin | Nystatin | 56 | 32 |
| Nystop | Nystatin | 56 | 35 |
| Trospium Chloride | Trospium Chloride | 56 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 53 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 52 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 52 | suppressed |
| Calcitriol | Calcitriol | 51 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 51 | suppressed |
| Mounjaro | Tirzepatide | 51 | suppressed |
| Novolog Flexpen | Insulin Aspart | 51 | 19 |
| Lovastatin | Lovastatin | 50 | suppressed |
| Metronidazole | Metronidazole | 50 | 19 |
| Amoxicillin | Amoxicillin | 48 | 18 |
| Humalog | Insulin Lispro | 48 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 17 |
| Haloperidol | Haloperidol | 46 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 45 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 45 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 45 | suppressed |
| Fluconazole | Fluconazole | 45 | 31 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 45 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 44 | 12 |
| Loperamide | Loperamide Hcl | 44 | 28 |
| Venlafaxine Hcl | Venlafaxine Hcl | 44 | suppressed |
| Carbamazepine Er | Carbamazepine | 43 | suppressed |
| Hydrocortisone | Hydrocortisone | 43 | suppressed |
| Ibuprofen | Ibuprofen | 43 | 13 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 43 | 15 |
| Calcium Acetate | Calcium Acetate | 42 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 30 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 42 | suppressed |
| Brilinta | Ticagrelor | 41 | suppressed |
| Fenofibrate | Fenofibrate | 41 | suppressed |
| Lorazepam | Lorazepam | 41 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 14 |
| Methotrexate | Methotrexate Sodium | 40 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 40 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 40 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Azithromycin | Azithromycin | 37 | 23 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 37 | 20 |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 37 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 37 | suppressed |
| Timolol Maleate | Timolol Maleate | 37 | 13 |
| Mirabegron Er | Mirabegron | 36 | suppressed |
| Ranolazine Er | Ranolazine | 36 | suppressed |
| Alprazolam | Alprazolam | 35 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 35 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 35 | 18 |
| Spiriva Respimat | Tiotropium Bromide | 35 | suppressed |
| Carbamazepine | Carbamazepine | 34 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 34 | suppressed |
| Methylprednisolone | Methylprednisolone | 34 | 23 |
| Valacyclovir | Valacyclovir Hcl | 34 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 33 | suppressed |
| Bumetanide | Bumetanide | 33 | suppressed |
| Lubiprostone | Lubiprostone | 33 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 33 | 11 |
| Albuterol Sulfate | Albuterol Sulfate | 32 | 17 |
| Betamethasone Valerate | Betamethasone Valerate | 32 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 32 | 14 |
| Methimazole | Methimazole | 32 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 32 | suppressed |
| Ramipril | Ramipril | 32 | suppressed |
| Enulose | Lactulose | 31 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 31 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 31 | 20 |
| Lurasidone Hcl | Lurasidone Hcl | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Anastrozole | Anastrozole | 29 | suppressed |
| Armour Thyroid | Thyroid,pork | 29 | suppressed |
| Benzonatate | Benzonatate | 29 | 11 |
| Bupropion Hcl | Bupropion Hcl | 29 | suppressed |
| Carbidopa | Carbidopa | 29 | suppressed |
| Phenytoin | Phenytoin | 29 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 29 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 29 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | suppressed |
| Perphenazine | Perphenazine | 28 | suppressed |
| Rexulti | Brexpiprazole | 28 | suppressed |
| Tacrolimus | Tacrolimus | 28 | suppressed |
| Gemtesa | Vibegron | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | 13 |
| Cefuroxime | Cefuroxime Axetil | 26 | 14 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 26 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 26 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 25 | suppressed |
| Dexamethasone | Dexamethasone | 24 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Lactulose | Lactulose | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | 11 |
| Nyamyc | Nystatin | 23 | 15 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 17 |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 22 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 22 | 14 |
| Restasis | Cyclosporine | 22 | suppressed |
| Acetic Acid | Acetic Acid | 21 | suppressed |
| Amantadine | Amantadine Hcl | 21 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 21 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 21 | suppressed |
| Ethosuximide | Ethosuximide | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Galantamine Er | Galantamine Hbr | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 16 |
| Sucralfate | Sucralfate | 20 | suppressed |
| Zonisamide | Zonisamide | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Konvomep | Omeprazole/Sodium Bicarbonate | 18 | suppressed |
| Levetiracetam Er | Levetiracetam | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Np Thyroid | Thyroid,pork | 18 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 17 | 17 |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| K-Phos Original | Potassium Phosphate,monobasic | 17 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Clozapine | Clozapine | 16 | suppressed |
| Daptomycin | Daptomycin | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 16 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 13 |
| Nadolol | Nadolol | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 16 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 14 | suppressed |
| Dulera | Mometasone/Formoterol | 14 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 14 | suppressed |
| Letrozole | Letrozole | 14 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 13 | suppressed |
| Sprycel | Dasatinib | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Ertapenem | Ertapenem Sodium | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Apidra Solostar | Insulin Glulisine | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Gvoke Hypopen 1-Pack | Glucagon | 11 | suppressed |
| Insulin Aspart | Insulin Aspart | 11 | suppressed |
| Lithostat | Acetohydroxamic Acid | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,773.42 · 61 records | PFIZER INC. | ABRYSVO, AREXVY, AUSTEDO XR, Arikayce, Auvelity, Brinsupri, COMIRNATY, Cologuard Collection Kit, Dojolvi, ELIQUIS, EOHILIA, FARXIGA, INGREZZA, INJECTAFER, INSPIRE, Kerendia, LEQVIO, NURTEC ODT, Nayzilam, ONPATTRO, OTEZLA, PREVNAR 20, QULIPTA, REPATHA, REXULTI, SPRAVATO, TONMYA, TRELEGY ELLIPTA, UBRELVY, VALTOCO, VRAYLAR, VYNDAQEL, Veozah, Wegovy, XIFAXAN, ZAVZPRET | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error